CAR T-Cell Therapy Market Segmentation:
End use Segment Analysis
Hospitals dominate the end use segment and are set to hold a share value of 87.6% in 2035. The segment is driven by its strong infrastructure and multidisciplinary staff to take on complex treatments and effects. Hospitals offer specialized facilities, including dedicated operating theatres and an ICU, that is necessary for administering CAR T-cell therapies. In addition, the July 2022 Science Direct report illustrates that the CAR T cell infusions for the majority of patients are 88% to 98% in hospitals. The hospitals also provide ongoing monitoring of treatment to make therapy safer and more effective.
Type Segment Analysis
In the type category, CAR T cell therapy dominates the segment and is expected to hold a significant share in 2035. The segment is driven by its revolutionary outcomes in hematologic cancers, mainly in B-cell lymphomas and leukemias, where traditional therapies are ineffective. With the support of FDA approvals and strong clinical trial pipelines, CAR T-cell treatments have shown high remission rates and durability compared to other treatments. The growth of the therapy is also driven by strategic partnerships with academia, biotech, and regulatory agencies for the efficient launch of next-generation products, assuring long-term leadership in the market.
Target Antigen Segment Analysis
Based on the target antigen, the CD19 segment is predicted to capture the largest share in the market over the assessed period. The clinical validation and regulatory recognition are the drivers dominating this segment. For instance, in 2024 alone, the FDA and EMA gave clearance for six different CD19-targeted therapies. On the other hand, the NLM study published in December 2023 depicts that CAR T-cell therapy for refractory or relapsed diffuse large B-cell lymphoma (DLBCL) reports objective responses in about 70% of patients, with a specific phase II ZUMA-1 trial reporting an overall response rate (ORR) of 82% and a complete response (CR) rate of 54%, highlighting the response rate from using this technology. Moreover, its proven efficacy in treating hematologic malignancies is solidifying its dominance over other types.
Our in-depth analysis of the CAR T-cell therapy market includes the following segments:
|
Segment |
Subsegments |
|
Type |
|
|
Target Antigen |
|
|
Indication |
|
|
Product |
|
|
Manufacturing Process |
|
|
End use |
|
